The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
Shandong Freda Biotech Co., Ltd. and its medical-aesthetic skincare brand Key C announced the presentation of a novel ...
Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...
Huonslab files BLA for HYDIZYME™, targeting MFDS approval in 2026 for its recombinant human hyaluronidase using HyDIFFUZE™.
THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...
Thought LeadersDr. Amy Sheng, Dr. Lurong PanTechnical Account Manager, CEOSino Biological Inc., Ainnocence In this interview, NewsMedical talks to Dr. Amy Sheng, a technical account manager at Sino ...
Antibody engineering and production are essential tools in drug discovery, providing powerful and specific therapeutics and diagnostic/prognostic materials for various diseases. Antibodies are ...
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respect to time ...
Amy Sheng (left) is Head of the CRO Program at Sino Biological US Inc. (PA, USA), and has expertise in cell, molecular biology, immunology and biochemistry. In this interview, Amy discusses the ...
Recombinant antibody technology has addressed many problems associated with hybridoma-based platforms, opening the door to a new class of biologics. Today, this technology continues to contribute to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback